We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The MHRA continues to speed up access to medicines for patients, increase efficiency of regulation and help to attract innovation and investment in the UK’s thriving £100 billion life sciences industry.
MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
MHRA and UK Border Force crack down on the illegal medicines trade in intensive 14-day international operation.
As with all medicines, we will continue to closely monitor the safety and effectiveness of linerixibat as it is used more widely.
The MHRA has limited the use of nasal decongestant sprays containing xylometazoline and oxymetazoline to a maximum of five days due to side effects of prolonged use.
The Medicines and Healthcare products Regulatory Agency (MHRA) is pleased to announce the appointment of Jason Bonander as its new Chief Digital and Technology Officer (CDTO).…
An MHRA-led investigation has exposed a £1.8 million illegal medicines and steroids network, leading to seven men being sentenced.
Patients in the UK to get access to new treatments faster and still safely under new clinical trial regulations coming into force on 28 April 2026.
First published during the 2024 to 2026 Starmer Labour government
As with any medicine, the MHRA will keep the safety and effectiveness of Enflonsia under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of Wegovy under close review.
MHRA and eBay partnership removes 215 listings of potentially dangerous medicines from the eBay platform highlighting the benefits of private/public working.
MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronemia syndrome
The MHRA continues to be at the forefront of innovation and secures multi-year funding to expand its pioneering AI Airlock programme.
The Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration are strengthening cooperation on medical device regulation, to support faster access to safe, innovative technologies for patients in both countries.
As with any medicine, the MHRA will keep the safety and effectiveness of sevabertinib under close review.
Medicines and Healthcare products Regulatory Agency (MHRA) takes decisive action to phase out animal testing by helping developers to make greater use of New Approach Methodologies (NAMs).
As a precautionary measure, Mölnlycke Health Care is recalling three batches of Hibiwash, an antimicrobial wash, due to microbial contamination at the manufacturing facility.
New pathway set to synchronise licensing and value assessment decisions
Expanding medicine reclassification could improve access to treatments, empower self-care, and reduce pressure on NHS services.
As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).